

Table 2 – Mean changes [and 95% CI] from baseline to 6 months follow-up in clinical parameters

	Empagliflozin (n = 22)	Sitagliptin (n = 22)	p value
<i>Weight (kg)</i>	-1.6 [-2.7/-0.5]*	0.1 [-1.1/1.2]	0.0315
<i>HR at rest (beat/min)</i>	0.6 [-1.6/2.8]	-0.4 [-4.5/3.7]	ns
<i>MAP rest (mmHg)</i>	-5.4 [-10.7/0.0]	-0.22 [-7.6/7.2]	ns
<i>HbA_{1c} (mmol/mol)</i>	-4.6 [-7.4/-1.8]*	-4.9 [-8.8/-0.9]*	ns
<i>Total Cholesterol (mg/dL)</i>	-8 [-21/5]	-15 [-30/0]	ns
<i>HDL-Cholesterol (mg/dL)</i>	1.3 [-1.4/4.0]	-1.7 [-4.2/0.9]	ns
<i>LDL-Cholesterol (mg/dL)</i>	-7 [-19/6]	-7 [-18/3]	ns
<i>Triglycerides (mg/dL)</i>	-2 [-28/24]	-14 [-33/6]	ns
<i>Hb (g/dL)</i>	0.7 [0.2/1.1]*	-0.5 [-1/-0.1]	0.0003
<i>Hct (%)</i>	2.0 [0.7/3.2]*	-1.3 [-2.6/0.0]	0.0006
<i>Creatinine (mg/dL)</i>	-0.1 [-0.2/0.1]	-0.0 [-0.1/0.0]	ns
<i>eGFR (mL/min/1.73mq)</i>	2.5 [-3.7/8.7]	1.4 [-1.8/4.6]	ns
<i>Uric acid (mg/dL)</i>	-1.5 [-2.3/-0.6]*	0.2 [-0.3/0.6]	0.0023
<i>ACR (mg/g)</i>	6.1 [-1.9/14.2]	5.0 [-20.6/30.5]	ns

* indicates a statistically significant difference within groups, p value indicates the level of statistical significance of the interaction term *time*treatment* at MANOVA